Intracellular Total Liab from 2010 to 2025

ITCI Stock  USD 126.20  0.06  0.05%   
Intracellular's Total Liabilities is increasing with slightly volatile movements from year to year. Total Liabilities is estimated to finish at about 165.3 M this year. Total Liabilities is the total amount of all liabilities that Intracellular Th has, including both short-term and long-term liabilities. View All Fundamentals
 
Total Liabilities  
First Reported
2011-12-31
Previous Quarter
175.9 M
Current Value
179.6 M
Quarterly Volatility
48.5 M
 
Yuan Drop
 
Covid
Check Intracellular financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Intracellular's main balance sheet or income statement drivers, such as Interest Expense of 8.9 M, Total Revenue of 560.7 M or Gross Profit of 520 M, as well as many indicators such as Price To Sales Ratio of 16.16, Dividend Yield of 0.0 or PTB Ratio of 7.67. Intracellular financial statements analysis is a perfect complement when working with Intracellular Valuation or Volatility modules.
  
Check out the analysis of Intracellular Correlation against competitors.

Latest Intracellular's Total Liab Growth Pattern

Below is the plot of the Total Liab of Intracellular Th over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Intracellular's Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Intracellular's overall financial position and show how it may be relating to other accounts over time.
Total Liab10 Years Trend
Slightly volatile
   Total Liab   
       Timeline  

Intracellular Total Liab Regression Statistics

Arithmetic Mean53,522,388
Geometric Mean25,885,477
Coefficient Of Variation106.85
Mean Deviation46,532,733
Median39,491,617
Standard Deviation57,186,951
Sample Variance3270.3T
Range162.4M
R-Value0.92
Mean Square Error541T
R-Squared0.85
Slope11,045,448
Total Sum of Squares49055.2T

Intracellular Total Liab History

2025165.3 M
2024157.4 M
2023136.9 M
202298.7 M
202172 M
202060.5 M
201956.2 M

About Intracellular Financial Statements

Investors use fundamental indicators, such as Intracellular's Total Liab, to determine how well the company is positioned to perform in the future. Although Intracellular's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Total Liabilities157.4 M165.3 M

Currently Active Assets on Macroaxis

When determining whether Intracellular Th offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intracellular's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intracellular Th Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intracellular Th Stock:
Check out the analysis of Intracellular Correlation against competitors.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.87)
Revenue Per Share
6.096
Quarterly Revenue Growth
0.39
Return On Assets
(0.07)
Return On Equity
(0.1)
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.